Berenberg analysts say AstraZeneca's new hypophosphatasia drug efzimfotase alfa can replace and expand the $2B Strensiq franchise. They raise peak sales estimate to $4.2B from $3B, citing a superior profile and significant unmet need in both pediatric and adult patients. Shares fell 1.6%.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
